We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
- Authors
Aranda, E; Manzano, J L; Rivera, F; Galán, M; Valladares-Ayerbes, M; Pericay, C; Safont, M J; Mendez, M J; Irigoyen, A; Arrivi, A; Sastre, J; Díaz-Rubio, E
- Abstract
Skin rash is an adverse event which might be associated with longer survival in patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. The aim of this nonrandomised phase II clinical trial is to prospectively evaluate the relationship between skin rash and overall survival (OS) in advanced/metastatic pancreatic cancer treated with erlotinib plus gemcitabine.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 7, p1919
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdr560